Fine print: New technique allows fast printing of microscopic electronics

29-Jan-2008 - A new technique for printing extraordinarily thin lines quickly over wide areas could lead to larger, less expensive and more versatile electronic displays as well new medical devices, sensors and other technologies. Solving a fundamental and long-standing quandary, chemical engineers at ...

Molecular Hand

DNA-based molecular machine that reversibly grabs and then releases thrombin

30-Jun-2004 - Nanorobots and molecular machines are no longer just a matter for the imaginations of science fiction writers; they have become a realistic goal of serious research. Researchers in Munich have now succeeded in constructing a type of "molecular hand," which can, upon application of an external ...

Dow and Plant Research International to Collaborate on Therapeutic Glycoprotein Production in Plants

06-Nov-2002 - The Dow Chemical Company and Plant Research International B.V. of Wageningen, The Netherlands, have agreed to join forces to speed development of therapeutic proteins with mammalian-like glycan structures in transgenic plants. Through their collaboration, the companies will work to expand the ...

Akzo Nobel launches Arixtra® in the United States

11-Feb-2002 - Arnhem/Oss, the Netherlands, – Akzo Nobel’s business unit Organon and Sanofi-Synthélabo today announced the launch of their antithrombotic drug Arixtra® in the United States. Arixtra, an innovative, synthetically-produced drug, is indicated for the prevention of deep vein thrombosis in patients ...

FDA Approves First Biologic Treatment for Sepsis

22-Nov-2001 - FDA today approved the first biologic treatment for the most serious forms of sepsis, a life-threatening illness caused by severe infection. The new treatment is a genetically engineered version of a naturally occurring human protein, Activated Protein C, which interferes with some of the body's ...

Tularik Receives Milestone Payment From Eli Lilly And Company

09-Nov-2001 - Tularik Inc. (Nasdaq: TLRK) today announced that its anti-thrombotic research collaboration with Eli Lilly and Company (NYSE: LLY) has successfully progressed to an advanced stage of preclinical development, triggering an undisclosed milestone payment to Tularik. As part of the July ...

Myriad Genetics Drug Enters Preclinical Testing for Prevention of Acute Thrombosis

02-May-2001 - Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has begun preclinical testing of its proprietary protein drug MPC-1203 for the treatment of acute thrombotic events such as those due to inflammation following major trauma, orthopedic or open heart surgery as well as for the ...

GlaxoSmithKline and Sepsicure, L.L.C. Announce a Licensing Agreement on Compound for Treating Sepsis

27-Feb-2001 - GlaxoSmithKline plc and Sepsicure, L.L.C. today announce that they have reached a licensing agreement on a compound for the treatment of sepsis, the often-fatal result of severe bacterial infections. The compound is about to enter Phase II clinical studies. Under terms of the agreement, ...

Lilly and Sankyo To Collaborate on Novel Oral Antithrombotic Compound

21-Dec-2000 - Eli Lilly and Company (NYSE: LLY and TSE: 4857) and Sankyo Company, Ltd. (TSE: 4501), announced they have signed a letter of intent to collaborate on CS-747, a potentially potent antiplatelet agent that blocks ADP receptors. CS-747 is being tested in Phase I human clinical trials for its ...

With Terlux from BASF: Greater transparency in medicine

14-Dec-2000 - One of the youngest plastics from BASF is Terlux®, a thermoplastic based on methyl methacrylate, acrylonitrile, butadiene and styrene - and consequently abbreviated to MABS. The monomer units are matched to one another in such a way that the resultant material is distinguished ...